Sacha El Khoury, MD
Research fellow
MD Anderson Cancer Center
Houston, Texas, United States
Abdelrahman Yousef, MD
Resident
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Sun Mi Lee, MD
Associate Professor
Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Wai Chin Foo, MD
Professor
Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Melissa Wainwright Taggart, MD
Professor
Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Paul F. Mansfield, MD
Professor
Department of Surgical Oncology, University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Keith F. Fournier, MD
Associate Professor
Department of Surgical Oncology, University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Beth A. Helmink, MD, PhD (she/her/hers)
Assistant Professor
Department of Surgical Oncology, University of Texas MD Anderson Cancer Center
Houston, Texas, United States
John P. Shen, MD (he/him/his)
Assistant Professor
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Yun Song, MD (she/her/hers)
Assistant Professor
Department of Surgical Oncology, University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Sara P. Ginzberg, MD, MS (she/her/hers)
Fellow, Complex General Surgical Oncology
MD Anderson Cancer Center
Houston, Texas, United States
Of 3,404 patients, 816 (24.0%) had LNM. Most patients had pT3 (1,907, 56.0%) or pT4 (1,307, 30.5%) disease. When histologic grade was available (2,348, 69.0%), 723 (30.8%) patients had G2 and 730 (31.0%) had G3 tumors. A RHC was performed in the setting of distant metastatic disease in 429 (12.6%) patients.
On multivariable analysis, age ³64 years (OR 1.34, p=0.005), Black race (OR 1.77, p< 0.001), Hispanic ethnicity (OR 1.89, p=0.033), increasing T stage (T3 OR 2.25, p=0.085; T4 OR 10.9, p< 0.001), increasing grade (G2 OR 1.31, p=0.100; G3 OR 3.98, p< 0.001), and presence of lymphovascular invasion (OR 5.82, p< 0.001) were significantly associated with LNM. The optimism-corrected area under the curve for the model was 0.856.
Based on the model, 196 (5.8%) patients were considered low risk (£5% LNM rate), 1,225 (36.0%) intermediate risk (5-10% LNM rate), and 1,983 (58.3%) high risk ( >10% LNM rate). The actual and predicted rates of LNM were: 2.0% and 2.0% (95% CI 1.9-2.0%) for low-risk, 6.2% and 6.5% (95% CI 6.2-6.8%) for intermediate-risk, and 37.1% and 36.9% (95% CI 35.8-38.1%) for high-risk patients.
Of 2,861 patients with follow-up data, LNM was associated with decreased 5-year OS rate (44.2% vs. 88.9%, log-rank p< 0.001), even in the presence of distant metastasis (16.2% vs 31.5%, log-rank p=0.002).
Conclusions: Regional LNM occurs in nearly one-quarter of patients with GCA, and only 6% of patients in a national cohort can be considered low risk. Accurate histopathologic assessment by an experienced gastrointestinal pathologist is crucial to defining risk. More evidence is needed before completion RHC can be omitted in a subset of patients with GCA.